GlassScriptPhysician profile
Sandeep K Malik
NPI 1154484525
$4,151.65
in general payments reported to CMS, 2019-2025
27 companies · $493 in 2025
The $493 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $464 · 2021: $1,007 · 2022: $696 · 2023: $765 · 2024: $436 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431 · Long Term Medical Supply Or Device Loan: $167 · Education: $96.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.44 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $96.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,194.40 | 2019-2023 | |
| Pfizer INC. | $682.53 | 2021-2025 | |
| Janssen Biotech, INC. | $420.81 | 2019-2025 | Erleada, Tecvayli, Darzalex |
| Genzyme Corporation | $321.07 | 2020-2024 | |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $163.64 | 2021-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $155.22 | 2021-2025 | Keytruda |
| Glaxosmithkline, LLC. | $144.26 | 2021-2025 | Jemperli, Zejula |
| Celgene Corporation | $136.22 | 2021-2023 | Pomalyst, Reblozyl |
| Daiichi Sankyo INC. | $93.65 | 2020-2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $91.75 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $72.51 | 2025 | Danziten |
| Seagen INC. | $61.15 | 2022-2023 | Padcev |
| Agios Pharmaceuticals, INC. | $56.82 | 2024-2025 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $54.85 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50.09 | 2019 | |
| Incyte Corporation | $46.00 | 2022-2023 | Jakafi |
| Verity Pharmaceuticals INC. | $44.36 | 2023 | Trelstar |
| Pharmacyclics LLC, An Abbvie Company | $33.48 | 2023 | Epkinly, Imbruvica |
| Stemline Therapeutics INC. | $29.88 | 2025 | Orserdu |
| Abbvie INC. | $27.22 | 2025 | |
| Taiho Oncology, INC. | $20.48 | 2019 | |
| Myriad Genetic Laboratories, INC. | $19.41 | 2025 | Precisetumor |
| Global Blood Therapeutics, INC. | $19.19 | 2022 | |
| Foundation Medicine, INC. | $15.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 | |
| Tersera Therapeutics LLC | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.